Analysis of the expression of microRNAs in myeloid leukemia, its use as a biomarker of the pathology

Authors

DOI:

https://doi.org/10.33448/rsd-v11i14.36538

Keywords:

Leukemia; MicroRNA; Biomarker.

Abstract

Leukemia has as its main characteristic the accumulation of leukocytes in the bone marrow and blood, with the classification of the place where it will affect and also the speed of progress of the disease. In terms of the progressive speed of this cancer, it stands out chronic and acute, more common in adults and with a delayed symptomatic manifestation and another more common in children and has about 80% of cure. The diagnosis is made through the signs and symptoms present by the patient and together with the blood count. Studies show that the use of miRNAS in the diagnosis of leukemia has become very promising, mainly because it is a painless, less invasive and safe technique, and can also be used to monitor the status of this neoplasm. As a statism, a study showed the use of these RNA molecules that are used to delay cellular apoptosis, consequently prolonging the quality of life of patients with leukemia. In view of these studies, a survey was carried out between August and October 2022, through a descriptive review and survey in the VHL and Pubmed databases, with the purpose of analyzing the profile of miRNAs present in AML and CML, allowing the distinction in the subtypes and degrees, as its association with the diagnosis, prognosis and therapeutic efficacy

References

Boechat, N., Bastos, M, M., Azevedo, L, D., & Oliveira, A. P. (2017). Sínteses e propriedades de fármacos inibidores da tirosina quinase BCR-ABL, utilizados no tratamento da Leucemia Mieloide Crônica. QUÍMICA NOVA (ONLINE), Vol. XY, 01-19.

Barbosa, M. G. A., & de Melo, A. T. (2020). Análise do perfil de miRNAs de leucemias linfocíticas. Brazilian Journal of Development, 6(12), 102464-102472.

Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., & Marcucci, G. (2010). Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences, 107(16), 7473-7478.

Bratz, B. S. G., Gatzke, M., & Frizzo, M. N. (2016). Aspectos Moleculares na Leucemia Linfoide Aguda: Uma Revisão. Newslab, 135 (2016), 1-15.

Butrym, A., Rybka, J., Baczyńska, D., Tukiendorf, A., Kuliczkowski, K., & Mazur, G. (2015). Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. Journal of Experimental & Clinical Cancer Research, 34(1), 1-5. for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. American journal of hematology, 86(2), 237.

Yin, X., Huang, S., Xu, A., Fan, F., Chen, L., Sun, C., & Hu, Y. (2020). Identification of distinctive long noncoding RNA competitive interactions and a six‐methylated‐gene prognostic signature in acute myeloid leukemia with− 5/del (5q) or− 7/del (7q). Journal of Cellular Biochemistry, 121(2), 1563-1574.

Yurt, Y., Ayyıldız, O., Nursal, A. F., & İsi, H. (2020). MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia.

Zhao, J., Lu, Q., Zhu, J., Fu, J., & Chen, Y. X. (2014). Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagnostic pathology, 9(1), 1-6.

Zhi, Y., Xie, X., Wang, R., Wang, B., Gu, W., Ling, Y., & Liu, Y. (2015). Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. International journal of hematology, 102(3), 296-303.

Zhi, Y., Xie, X., Wang, R., Wang, B., Gu, W., Ling, Y., & Liu, Y. (2015). Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. International journal of hematology, 102(3), 296-303.

Zhou, J. D., Zhang, L. C., Zhang, T. J., Gu, Y., Wu, D. H., Zhang, W., & Qian, J. (2018). Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia. Journal of translational medicine, 16(1), 1-10.

Published

28/10/2022

How to Cite

BARROS, Émerson F. A.; SOUZA, T. F. M. P. .; BARBOSA, M. G. A. . Analysis of the expression of microRNAs in myeloid leukemia, its use as a biomarker of the pathology. Research, Society and Development, [S. l.], v. 11, n. 14, p. e391111436538, 2022. DOI: 10.33448/rsd-v11i14.36538. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/36538. Acesso em: 10 dec. 2022.

Issue

Section

Health Sciences